Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 86 of 228 for:    yeast

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02740790
Recruitment Status : Unknown
Verified March 2017 by Shanghai Zerun Biotechnology Co.,Ltd.
Recruitment status was:  Active, not recruiting
First Posted : April 15, 2016
Last Update Posted : March 8, 2017
Sponsor:
Information provided by (Responsible Party):
Shanghai Zerun Biotechnology Co.,Ltd

Brief Summary:
Evaluate immunogenicity and safety of recombinant human papillomavirus bivalent ( types 16 and 18 ) vaccine ( Yeast )in different age group. And evaluate persistence of immune response in 9-17years age group. To demonstrate that 9-17years age group was non-inferior to 18-26 years age group and 27-45 years age group in terms of immunogenicity.

Condition or disease Intervention/treatment Phase
Human Papillomavirus Biological: HPV vaccine Biological: Placebo Phase 2

Detailed Description:

This study is a multi-centre, randomized, blinded, placebo controlled study. The study vaccine is recombinant human papillomavirus bivalent (types 16 and 18) vaccine (Yeast), the placebo is aluminium phosphate diluent.

After informed and received the consent of participants/guardians, 1200 healthy females aged 9-45 will be enrolled into three age groups: 9-17, 8-26, 27-45. With the proportion of 1:1, vaccine group and placebo group will receive injection of 0.5ml of vaccine or placebo diluent.

Participants will be injected of vaccine or placebo on a three-dose schedule (0, 2, 6 months). After each inoculation, the immediate reaction will be observed for 30 minutes, and the local and systemic reaction will be systematically observed for 7 days. After the first inoculation, adverse event will be collected until one month after the final inoculation, while serious adverse event will be collected until 6 months after the final inoculation. For every participants, blood samples will be collected before the first inoculation (month 0), one month after the final inoculation (month 7), 6 months after the final inoculation (month 12) to detect the neutralizing antibody of HPV type 16 and 18, and proceed safety and immunogenicity analysis. For participants in 9-14 age group who received the vaccine, neutralizing antibody will also be detected in month 24, 36 and 48 to examine the immune persistency. Meanwhile, some participants will be chosen to study the deviation of gene expression after the vaccination and the association of that with the neutralizing antibody level.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety of Recombinant Human Papillomavirus Bivalent(Type 16 and 18) Vaccine (Yeast) in Healthy Females
Study Start Date : September 2013
Actual Primary Completion Date : April 2016
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HPV vaccine 1
300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
Biological: HPV vaccine
Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Placebo Comparator: Placebo 1
300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule Placebo.
Biological: Placebo
Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Experimental: HPV vaccine 2
120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
Biological: HPV vaccine
Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Experimental: HPV vaccine 3
180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
Biological: HPV vaccine
Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Placebo Comparator: Placebo 2
120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule Placebo.
Biological: Placebo
Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Placebo Comparator: Placebo 3
180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule Placebo.
Biological: Placebo
Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule




Primary Outcome Measures :
  1. The neutralizing antibody responses of HPV 16/18 after vaccination by measuring Geometric Mean Titer (GMT). [ Time Frame: 1 month after vaccination ]

Secondary Outcome Measures :
  1. Occurrence, intensity and relationship to vaccination of any solicited local or systemic reactions [ Time Frame: 7 days after each vaccine dose ]
  2. Occurrence, intensity and relationship to vaccination of any solicited local or systemic reactions [ Time Frame: 6 months after finish vaccinations ]
  3. The durability of neutralizing antibody responses of HPV 16/18 after vaccination. [ Time Frame: 48 months after finish vaccinations ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   9 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy female between, and including, 9 and 45 years of age at the time of the first vaccination
  • Provide legal identification for for the sake of recruitment
  • Be able to understand and sign informed consent prior to enrollment (For subjects below the legal age of consent, informed consent must be signed by parent(s)/legal guardian(s) in addition).
  • Subject must be not pregnant at the enrollment and agree to using adequate contraceptive precautions within 7 months.

Exclusion Criteria:

  • History of cervical cancer
  • Previous administration of any HPV vaccine
  • History of severe allergic reaction requiring medical intervention (such as oral and throat swelling, difficulty breathing, hypotension or shock)
  • History of allergic to vaccine, or to any ingredient of vaccine.
  • History of epilepsy, seizures or convulsions, or family history of mental illness
  • Subjects are immunocompromised or have been diagnosed as suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation (JRA), inflammatory bowel disease or other autoimmune diseases, administration of immunosuppressants with six months prior to the first vaccine dose.
  • History of asthma, thyroidectomy, angioneurotic edema, diabetes or malignant
  • Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy
  • Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency, coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder
  • Acute disease or chronic disease acute exacerbation 7 days prior to vaccination
  • Administration of immunoglobulins and/or any blood products within 3 months, or administration of any live attenuated vaccine within 28 days, or administration of any subunit or inactivated vaccines within 14 days.
  • Fever or axillary temperature> 37.0 °C before vaccination
  • During menstrual period, breastfeeding, pregnancy(pregnancy test positive), or planned pregnant within 7 month
  • History of hypertension, physical examination systolic blood pressure> 150mmHg and/or diastolic blood pressure> 100mmHg
  • Abnormal laboratory tests parameters
  • Any clinical significant disease or findings during study screening that, in the opinion of the Investigator may interfere with the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02740790


Locations
Layout table for location information
China, Guangxi
GuangXi Center for Diseases Control and Prevention
Nanning, Guangxi, China
Sponsors and Collaborators
Shanghai Zerun Biotechnology Co.,Ltd
Investigators
Layout table for investigator information
Principal Investigator: Rong-cheng Li, MD Guangxi Centers for Disease Control and Prevention

Layout table for additonal information
Responsible Party: Shanghai Zerun Biotechnology Co.,Ltd
ClinicalTrials.gov Identifier: NCT02740790     History of Changes
Other Study ID Numbers: 311-HPV-1002
First Posted: April 15, 2016    Key Record Dates
Last Update Posted: March 8, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Shanghai Zerun Biotechnology Co.,Ltd:
Human papillomavirus
vaccine
cervical infection
cervical cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs